Wilson Sonsini Advises Digestiva on $18.4 Million Series A Financing

On July 15, 2024, Digestiva, a leading food biotech company, successfully closed its Series A equity financing round, raising $18.4 million. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. Digestiva's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design. Wilson Sonsini Goodrich & Rosati represented Digestiva in the transaction.

Digestiva focuses on the discovery and development of proprietary protease enzymes designed to address critical challenges in protein nutrition, functionality, and overall health. The company's proteases enhance protein bioavailability, allowing people and animals to maximize nutritional benefits from existing diets without increasing protein consumption. These science-driven solutions have the potential to address global malnutrition and promote sustainable nutrition by improving health outcomes and reducing environmental impact. Alongside the Series A financing, Digestiva has entered into an exclusive manufacturing partnership with Magdalena. Under this agreement, Magdalena will enable the scale-up production of enzymes to help Digestiva reach its commercial milestones.

The Wilson Sonsini team that represented Digestiva includes Elton Satusky, Roy Argand, and Davelyn Couch.

For more information, please see the press release.